Abstract
OKT3, a monoclonal antibody against the CD3 cell population, was introduced to hepatic transplantation in the mid-1980s for the treatment of steroid resistant rejection (1–3). For didactic purposes, the indications for OKT3 therapy may be divided into three broad categories: 1) as a rescue therapy for steroid resistant rejection; 2) as prophylactic (induction) therapy; and, 3) as the initial therapy of rejection with the goal of eliminating high doses of steroids during the period of convalescence. The results for the first two indications have been the subject of several publications (1–4) and will not be addressed in this manuscript. Instead, we will report our experience with the use of OKT3 for the initial treatment of rejection. In addition, our experience with the use of this monoclonal antibody in patients with postoperative renal failure, positive crossmatches or ABO incompatibility will also be reported.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Starzl TE, Fung JJ. Orthoclone OKT3 intreatment of allografts rejected under cyclosporine-steroid therapy. Transplant Proc 18: 937, 1986.
Esquivel CO, Fung JJ, Markus B, et al. OKT3 in the reversal of acute hepatic allograft rejection. Transplant Proc 19: 2443, 1987.
Markus BH, Fung JJ, Gordon RD, et al. Effect of OKT3 on survival and rate of retransplantation. Transplant Proc 19: 61, 1987.
McDiarmid SV, Busuttil RW, Levy P, et al: The long-term outcome of OKT3 compared with cyclosporine prophylaxis after liver transplantation. Transplantation 52: 01–97, 1991.
Szpakowski J-L, Cox K, Nakazato P, et al. Experiences with the first 100 liver transplants at the Pacific Transplant Institute in San Francisco. Western J Med In Press.
Starzl TE, Iwatsuki S, Van Thiel DH: Evolution of liver transplantation. Hepatology 2: 614–636, 1982.
Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al: Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 323: 1723–28, 1990.
Nalesnik MA, Makowka L, Starzl TE: The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Prob Surg 25: 371–372, 1988.
Gorensek MJ, Stewart RW, Keys TF: Decreased infections in cardiac transplant recipients on cyclosporine with reduced corticosteroid use. Clev J Med 56: 690–5, 1989.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Esquivel, C.O., Nakazato, P., Concepcion, W., Szpakowski, J.L., Gettys, C., Lim, J. (1993). Practical Uses of OKT3. In: Galmarini, D., Fassati, L.R., Paoletti, R., Sherlock, S. (eds) Drugs and the Liver: High Risk Patients and Transplantation. Medical Science Symposia Series, vol 4. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-1994-8_23
Download citation
DOI: https://doi.org/10.1007/978-94-011-1994-8_23
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-5748-6
Online ISBN: 978-94-011-1994-8
eBook Packages: Springer Book Archive